NCT01936961撤回不适用
A Pilot Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid Tumors (I-CREST)
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 试验地点
- 1
- 主要终点
- Complete Response
研究概览
简要总结
The purpose of this study is to use Immunochemotherapy +/- Hypofractionated Radiation for complete response in solid tumors
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient has definitive histologically or cytologically confirmed metastatic NSCLC, colon, or TNB cancer.
- •Patient has one or more metastatic tumors measurable by CT scan (or PET/CT, if patient is allergic to CT contrast media).
- •For NSCLC patients without EGFR or ALK abnormalities amenable to EGFR or ALK targeted therapy: patients must have received no more than at least 2 or 3 cycles of either first- or second-line systemic therapy for the treatment of metastatic disease. For NSCLC patients with EGFR or ALK abnormalities amenable to receive EGFR or ALK targeted therapy: patients must have progressed on first-line EGFR or ALK targeted therapy and received no more than at least 2 or 3 cycles of either second- or third-line systemic therapy for the treatment of metastatic disease.
- •For colon cancer patients: patients must have patients must have received no more than at least 2 or 3 cycles of either first- or second-line systemic therapy for the treatment of metastatic disease.
- •For TNB cancer patients, patients must have patients must have received no more than at least 2 or 3 cycles of either first- or second-line systemic therapy for the treatment of metastatic disease.
- •At the time of screening, all patients must have scans (within 28 days) showing stable disease by RECIST 1.
- •Where applicable, measurable tumor marker (e.g. CA19-9, CEA, or CA125) collected within 14 days must be at least 10% less than baseline value on most recent systemic therapy (baseline value has to be abnormal elevated).
- •Patient has adequate biological parameters as demonstrated by the following blood counts at time of screening:
- •Absolute neutrophil count (ANC) > 1500 mm3, platelet count ≥ 100×109 L, hemoglobin ≥ 9 g/dL.
- •Serum creatinine ≤2.0, total bilirubin ≤ 2 mg/dL, AST/ALT ≤ 5 times the upper limit of normal range
- •Thyroid stimulating hormone (TSH) within institutional normal limits. If TSH is above the upper limit of normal range, then a free T4 within institutional normal limits is acceptable.
- •Persistent prior systemic therapy non-hematologic AE grade ≥2 (except alopecia or correctable electrolyte abnormality with supplementation)
- •Patient has a Karnofsky performance status (KPS) ≥
- •Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically sterile) must be willing to use an acceptable contraceptive method (abstinence, oral contraceptive or double barrier method) for the duration of the study and for 30 days following the last dose of study drug, and must have a negative urine or serum pregnancy test within 2 weeks prior to beginning treatment on this trial.
排除标准
- •Active clinically serious infection > CTCAE (version 4.03) Grade
- •Serious non-healing wound, ulcer, or bone fracture.
- •Patient has known brain metastases, unless previously treated and well-controlled for at least 1 month (defined as clinically stable, no edema, no steroids and stable in 2 scans at least 4 weeks apart).
- •Inability to complete informed consent process and adhere to the protocol treatment plan and follow-up requirements.
- •Patient has known active infection with HIV, hepatitis B, or hepatitis C (patients are NOT required to be tested for the presence of such viruses prior to therapy on this protocol).
- •Requiring daily corticosteroid dose ≥ 7.5 mg prednisone or equivalent per day.
- •Patient has undergone major surgery, other than diagnostic surgery (e.g., surgery done to obtain a biopsy for diagnosis without removal of an organ), within 4 weeks prior to Day 1 of treatment in this study.
- •Patient has a history of allergy or hypersensitivity to any of the study drugs or any of their excipients, or the patient exhibits any of the events outlined in the Contraindication or Special Warnings and Precautions sections of the product or comparator SmPC or Prescribing Information.
- •Patient has serious medical risk factors involving any of the major organ systems, or serious psychiatric disorders, which could compromise the patient's safety or the study data integrity.
- •Patient will be receiving any other anti-cancer therapy during participation in this trial.
研究组 & 干预措施
CTLA-4 Antibody + hypofractionated radiotherapy
Experimental
Hypofractionated radiotherapy completed at least 3 days prior to receipt of CTLA-4 Antibody
干预措施: CTLA-4 Antibody (Drug)
CTLA-4 Antibody + hypofractionated radiotherapy
Experimental
Hypofractionated radiotherapy completed at least 3 days prior to receipt of CTLA-4 Antibody
干预措施: Hypofractionated Radiotherapy (Radiation)
结局指标
主要结局
Complete Response
时间窗: One year
Complete response by immune-related response criteria (irRC)
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Shorter Course Radiation for the Treatment of Breast Cancer That Has Spread to Lymph NodesBreast CancerNCT02700386University of Colorado, Denver108
已完成
不适用
Hypofractionated Radiation Therapy to Improve Immunotherapy Response in Non-Small Cell Lung CancerNon Small Cell Lung Cancer MetastaticNCT03035890West Virginia University35
招募中
2 期
Hypofractionated RadiochemotherapyUterine Cervix CancerNCT06331468Denise Fabian20
已完成
2 期
Hypofractionated Radiation Therapy in Treating Participants With Breast Cancer Before SurgeryAnatomic Stage I Breast Cancer AJCC v8Anatomic Stage IA Breast Cancer AJCC v8Anatomic Stage IB Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8Prognostic Stage I Breast Cancer AJCC v8Prognostic Stage IA Breast Cancer AJCC v8Prognostic Stage IB Breast Cancer AJCC v8Prognostic Stage IIA Breast Cancer AJCC v8NCT03624478Mayo Clinic25
已完成
1 期
Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic CancersMetastaticNon Small Cell Lung Cancer (NSCLC)Breast CancerPancreatic CancerMelanomaNCT02639026Abramson Cancer Center at Penn Medicine53